Details for New Drug Application (NDA): 062435
✉ Email this page to a colleague
NDA 062435 describes SEFFIN, which is a drug marketed by Glaxosmithkline and is included in one NDA. Additional details are available on the SEFFIN profile page.
The generic ingredient in SEFFIN is cephalothin sodium. There are seven drug master file entries for this compound. Additional details are available on the cephalothin sodium profile page.
The generic ingredient in SEFFIN is cephalothin sodium. There are seven drug master file entries for this compound. Additional details are available on the cephalothin sodium profile page.
Summary for 062435
| Tradename: | SEFFIN |
| Applicant: | Glaxosmithkline |
| Ingredient: | cephalothin sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062435
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | Nov 15, 1983 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL | ||||
| Approval Date: | Nov 15, 1983 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 10GM BASE/VIAL | ||||
| Approval Date: | Nov 15, 1983 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
